Ideanomics Inc (NASDAQ: IDEX) announced that its subsidiary, Solectrac, has named Mani Iyer as CEO, placing the company for the business and delivery scale of its ground-breaking electronic tractors.
Iyer has more than 28 years of experience in the agriculture sector
Iyer, a 28-year old-timer of the agrarian and building businesses, essences in the homestead tractor grouping and has served a wide diversity of management locations in North America, South America, and Asia. Iyer’s know-how includes global equipment deals and promotion, corporate strategy and growth, channel growth, supply chain organization, product support and service, industrial, and quality declaration.
“Solectrac is the prospect of maintainable farming, and I am buoyant in his aptitude to manage the company through fast growth and development in the coming months as the agricultural and usefulness operation subdivisions changeover to cleaner and more effectual equipment replacements,” said Alf Poor, CEO of Ideanomics.
Before joining Ideanomics, Iyer functioned as president of LiuGong North America and president and CEO of Mahindra Agriculture Americas. He led the nearly unidentified brand to a “top three” location in the North American marketplace.
Adverum Biotechnologies Inc (NASDAQ: ADVM) Announces Selection of Jon Williams, Ph.D., as Vice President, Scientific Matters
Adverum Biotechnologies Inc (NASDAQ: ADVM) announced the selection of Jon Williams, Ph.D., as vice president, scientific matters, operative instantly. Dr. Williams will deliver technical and procedural know-how and management across Adverum’s scientific growth package for ADVM-022, reporting to Julie Clark, M.D., chief medical officer.
“Jon is a lively expert and inexhaustible circulated investigator, bringing 25 years of knowledge in scientific and preclinical medication and medical device growth and supervisory plans to this new locus at Adverum,” said Julie Clark, M.D., chief medical officer at Adverum Biotechnologies. “His complete familiarity of ocular diseases counting angiogenic retinal illness, planned scientific pilot design and implementation across all stages of ophthalmic product growth will be treasured for our ADVM-022 scientific growth package and our pipeline.”
Williams joins Adverum from Bausch Health Companies, where he functioned as senior director, scientific affairs and was accountable for leading scientific science and medicinal script for ophthalmic medicinal expedient schemes.